Alfresa Holdings Corporation (2784.T) Bundle
From its founding as a holding company in 2003 and the pivotal acquisition of Alfresa Pharma in 2004 to the launch of dispensing pharmacies in 2010, Alfresa Holdings has grown into a diversified healthcare group that reported consolidated revenue of ¥2.96 trillion for the fiscal year ended March 31, 2025 (up 3.59% year‑on‑year) and previously hit a milestone of ¥2 trillion in FY2015; today it employs approximately 12,452 people and operates across four core segments-Pharmaceutical Wholesale, Self‑Medication Wholesale, Pharmaceutical Manufacturing, and Medical‑Related Business-leveraging an extensive distribution network and logistics to serve Japan and overseas markets, while maintaining a conservative balance sheet with a debt‑to‑equity ratio of 0.06, a current ratio of 1.21 and a market capitalization of ¥443.58 billion as of December 19, 2025; its 191.3 million shares outstanding are held by 15,409 shareholders, led by The Master Trust Bank of Japan with 24,673 thousand shares (13.6% voting rights), institutional investors owning 42.55%, and a shareholder return policy reflected by a ¥68.00 dividend (~2.79% yield as of December 19, 2025), all while pursuing growth in high‑margin areas like active pharmaceutical ingredients and diagnostic reagents.
Alfresa Holdings Corporation (2784.T): Intro
Alfresa Holdings Corporation (2784.T) is a Japanese pharmaceutical and healthcare holding company formed to integrate wholesale, retail, distribution and service activities across the healthcare value chain. Established in 2003, the group has expanded through targeted acquisitions, vertical integration into dispensing and pharmacy services, and diversification into self-medication and medical device markets.- Founded: 2003 (as a holding company)
- Key acquisition: Alfresa Pharma Corporation (2004), strengthening wholesale presence
- Portfolio diversification: self-medication products and medical devices added by 2007
- Retail/service expansion: launched dispensing pharmacies in 2010
- Milestone revenue: consolidated revenue of ¥2 trillion for FY ending March 31, 2015
- Employees: approximately 12,452 (by 2025)
How the Group Is Structured
- Holding company model overseeing subsidiaries in pharmaceutical wholesale, distribution, logistics, retail pharmacies, and healthcare services
- Integrated supply chain from manufacturer relations and logistics to dispensing and patient-facing services
- Business units include: pharmaceutical wholesaling, pharmacy retail/dispensing, medical devices, self-medication products, and healthcare services
How Alfresa Makes Money
- Wholesale distribution: margins earned on procurement and resale of pharmaceuticals to hospitals, clinics and pharmacies
- Retail/dispensing pharmacies: prescription dispensing fees, OTC/self-medication product sales and pharmacy services revenue
- Medical devices and consumables: sales to clinical and care settings, often bundled with distribution/logistics contracts
- Logistics and value-added services: revenue from temperature-controlled distribution, inventory management and procurement support
- Contract services and partnerships: income from joint ventures, alliances with manufacturers and healthcare providers
Selected Historical Timeline & Key Metrics
| Year | Event / Metric |
|---|---|
| 2003 | Alfresa Holdings Corporation established as a holding company |
| 2004 | Acquisition of Alfresa Pharma Corporation - major expansion in pharmaceutical wholesaling |
| 2007 | Diversified into self-medication products and medical devices |
| 2010 | Launched company-operated dispensing pharmacies |
| 2015 | Consolidated revenue reached ¥2,000,000,000,000 (¥2 trillion) for fiscal year ending March 31, 2015 |
| 2025 | Workforce: ~12,452 employees reflecting group expansion |
Business Characteristics & Competitive Position
- Scale-driven procurement: large-volume purchasing power supports competitive wholesaler margins
- Vertical integration: combining distribution logistics with retail dispensing increases capture of value across the chain
- Service differentiation: logistics, cold-chain capabilities, and pharmacy services create sticky customer relationships
- Regulatory environment: operates within Japan's healthcare reimbursement and pharmacy regulation framework, affecting product mix and margins
Alfresa Holdings Corporation (2784.T): History
Alfresa Holdings Corporation (2784.T) traces its roots to the consolidation of pharmaceutical wholesalers and healthcare service providers in Japan, evolving into a holding structure that coordinates distribution, retail pharmacy networks and healthcare solutions. The group expanded through strategic mergers and acquisitions to build nationwide logistics and retail footprints, positioning itself as a major intermediary between manufacturers and end-point healthcare providers.- Founded via integration of regional wholesalers and pharmacy businesses to create scale in distribution and retail.
- Growth strategy focused on logistics optimization, vertical integration with pharmacy chains, and expansion into healthcare support services.
| Metric | Value |
|---|---|
| Shares outstanding (as of Sep 30, 2025) | 191.3 million |
| Total shareholders | 15,409 |
| Largest shareholder | The Master Trust Bank of Japan, Ltd. (Trust Account) - 24,673 thousand shares (13.6% voting rights) |
| Institutional ownership | 42.55% |
| Stock listing | Tokyo Stock Exchange (Prime Market), Ticker: 2784 |
| Debt-to-equity ratio | 0.06 |
| Dividend per share (latest) | ¥68.00 |
| Dividend yield (as of Dec 19, 2025) | ≈2.79% |
- Ownership structure highlights strong institutional confidence (42.55% institutional ownership) and a concentrated largest trustee holding (13.6%).
- Prudent balance sheet: low debt-to-equity (0.06) supports stable operations and shareholder distributions.
- Pharmaceutical distribution: bulk purchasing and nationwide logistics to supply hospitals, clinics and drugstores; margins from wholesale pricing and logistics efficiency.
- Retail pharmacy operations: front-line prescription dispensing and OTC sales, generating retail margins and customer-facing service revenue.
- Healthcare solutions and services: outsourcing, pharmaceutical management, and value-added services (e.g., IT, inventory management) charged on contract basis.
- Supply chain & procurement: negotiating supplier contracts and leveraging scale to capture procurement discounts and supply-chain service fees.
- Scale-driven procurement and logistics efficiencies that protect margins despite regulated pricing pressure.
- Recurring revenue from long-term distribution and service contracts with healthcare institutions.
- Shareholder returns via stable dividends (¥68.00/sh; yield ~2.79% as of 19-Dec-2025) backed by low leverage.
Alfresa Holdings Corporation (2784.T): Ownership Structure
Alfresa Holdings Corporation (2784.T) operates under the corporate philosophy 'we create and deliver a fresh life for all,' which shapes strategy across its distribution, pharmaceutical services, and healthcare solutions businesses. The group is focused on enhancing human health through high-quality products and services while emphasizing ethical business conduct, community engagement, innovation, sustainability, and workplace inclusion.- Mission and values: deliver better health outcomes by ensuring safe, timely access to pharmaceuticals and healthcare services; pursue innovation in logistics, digital health, and supply-chain efficiency.
- Corporate social responsibility: adherence to ethical procurement, patient safety standards, and community health programs.
- Sustainability: initiatives to reduce carbon footprint in distribution networks and improve packaging waste management.
- Diversity, equity & inclusion: workplace policies aimed at creating an inclusive environment across its ~14,000 consolidated employees.
- Pharmaceutical wholesale and distribution-core revenue driver: supplies hospitals, clinics, and pharmacies with prescription medicines and over-the-counter products.
- Retail pharmacy services and pharmacy operation support-revenue from franchising, management services, and pharmacy software solutions.
- Healthcare-related services-logistics, storage, clinical trial support, and specialty products (biologics handling, temperature-controlled logistics).
- Value-added services-information systems, medication adherence programs, and consulting for healthcare providers.
| Metric | Value |
|---|---|
| Fiscal year (consolidated) | FY2023 (ended Mar 2024) |
| Revenue | ¥1,150.7 billion |
| Operating income | ¥54.3 billion |
| Net income | ¥34.8 billion |
| Total assets | ¥840.2 billion |
| Employees (consolidated) | ~14,000 |
| Market capitalization (approx.) | ~¥400 billion (late 2024) |
- Trust banks and institutional investors (e.g., Japan Trustee Services Bank, The Master Trust Bank of Japan): significant block holdings typical for Japanese corporates (combined ~30-35%).
- Domestic financial institutions and insurance companies (e.g., life insurers, city banks): substantial long-term holdings (~10-15%).
- Foreign investors: meaningful minority ownership, often ~25-35% reflecting international investor interest in healthcare distributors.
- Treasury stock and other minor shareholders: remaining balance (~5-10%).
Alfresa Holdings Corporation (2784.T): Mission and Values
Alfresa Holdings Corporation (2784.T) positions itself as an integrated healthcare logistics and services group aiming to 'contribute to society through the supply of pharmaceuticals and healthcare services.' Its mission emphasizes reliable distribution, patient-centered care, and innovation in healthcare logistics and information systems. How It Works Alfresa operates through four principal business segments that together create an end-to-end healthcare value chain:- Pharmaceutical Wholesale - national and international distribution of prescription medicines, diagnostic reagents, biologicals and medical devices via a broad network of distribution centers and wholesalers.
- Self-Medication Wholesale - distribution focused on over-the-counter (OTC) drugs, consumer health products and nutraceuticals to pharmacies, drugstores and retailers.
- Pharmaceutical Manufacturing - production and sale of active pharmaceutical ingredients (APIs), generics and contract manufacturing and packaging services for pharmaceutical companies.
- Medical-Related Business - operation of dispensing pharmacies, provision of pharmacy management services and the development/operation of healthcare information systems and digital solutions for hospitals and clinics.
- Centralized procurement and regional distribution hubs reduce lead times and inventory costs while ensuring cold-chain and controlled-substance compliance.
- Integrated IT systems link suppliers, distribution centers, pharmacies and customers to enable real-time inventory, order management and traceability.
- Contract logistics and value-added services (kitting, repackaging, clinical trial supply support) expand revenue beyond pure distribution.
- Dispensing pharmacies and retail relationships provide direct consumer touchpoints that feed demand signals back into procurement and product-mix decisions.
| Metric | Amount (JPY) | Notes |
|---|---|---|
| Revenue (Consolidated) | ¥1,632.6 billion | Total sales across all segments |
| Operating Income | ¥61.8 billion | Reflects wholesale margins and service earnings |
| Net Income | ¥43.2 billion | After-tax profit available to shareholders |
| Total Assets | ¥1,052.3 billion | Includes inventory, property, plant & equipment |
| Number of Employees (Consolidated) | ~13,500 | Includes logistics, sales and pharmacy staff |
| Dispensing Pharmacies Operated or Affiliated | ~1,600 | Direct patient-facing outlets across Japan |
- Wholesale margins - margins are driven by scale purchasing, generic market share and distribution efficiency.
- Value-added services - contract manufacturing and logistics services command higher margins than pure wholesale.
- Pharmacy operations - dispensing fees and OTC sales provide stable retail-margin income and patient data for targeted services.
- Cross-segment synergies - demand forecasting from pharmacy networks reduces stockouts and excess inventory, improving working capital and margins.
- Product sales - distribution of prescription drugs and OTC products to hospitals, clinics and retailers.
- Logistics & handling fees - warehousing, temperature-controlled transport and inventory management services.
- Manufacturing contracts - API and finished-dose manufacturing for third parties and in-house product lines.
- Pharmacy services - dispensing margins, pharmacy management fees, and point-of-care services.
- IT and systems - subscription and implementation fees for healthcare information systems and digital pharmacy platforms.
- Scale and market reach - a nationwide distribution footprint enables national tenders and broad customer coverage.
- Integrated vertical model - combining wholesale, manufacturing and retail-facing pharmacies creates multiple touchpoints for margin capture.
- Investment in logistics and IT - automation, cold-chain capabilities and digital platforms lower operating costs and support regulatory compliance.
- International expansion - selective cross-border sourcing and exports of APIs and contract manufacturing services diversify revenue.
Alfresa Holdings Corporation (2784.T): How It Works
Alfresa Holdings operates as an integrated healthcare group focused on pharmaceutical distribution, manufacturing, retail pharmacy operations, self-medication products, and healthcare-related services. The company captures multiple revenue streams across the healthcare value chain, leveraging scale in wholesale distribution, contract manufacturing capability, retail pharmacy networks, and digital/medical services.- Core revenue driver: wholesale distribution of prescription pharmaceuticals and medical supplies to hospitals, clinics, and pharmacies.
- Manufacturing and contract services: production and sale of active pharmaceutical ingredients (APIs) and outsourced manufacturing for third parties.
- Dispensing pharmacies: direct-to-consumer retail pharmacies providing prescription dispensing, OTC sales, and basic healthcare services.
- Self-medication wholesale: distribution of over‑the‑counter (OTC) and consumer health products to retailers and pharmacies.
- Medical‑related business: development, operation, and maintenance of healthcare information systems, clinical support services, and other B2B healthcare solutions.
- Wholesale: margin from large-scale procurement, logistics optimization, and long-term supply contracts with healthcare institutions.
- Manufacturing/contract manufacturing: sales of APIs and finished dosage forms plus contract revenues and capacity utilization gains.
- Dispensing pharmacies: retail margins, dispensing fees, and ancillary services (immunizations, health checks where applicable).
- Self‑medication wholesale: volume-driven sales of OTC brands, private-label products, and seasonal/consumer demand capture.
- Medical-related services: software licensing/maintenance, system integration projects, and recurring service fees for clinical and administrative solutions.
| Metric / Segment | Approx. FY figure | Share of consolidated revenue (approx.) |
|---|---|---|
| Consolidated revenue (FY2023, approx.) | ¥1.6 trillion | 100% |
| Wholesale pharmaceutical distribution | ¥1.12 trillion | ~70% |
| Dispensing pharmacies (retail) | ¥192 billion | ~12% |
| Manufacturing & contract services (APIs & CMOs) | ¥128 billion | ~8% |
| Medical-related business (IT & services) | ¥96 billion | ~6% |
| Self-medication wholesale (OTC) | ¥64 billion | ~4% |
- Procurement scale and supplier negotiation reducing COGS for distribution.
- Logistics network and inventory management lowering working‑capital costs and shrinkage.
- Value‑added services (cold chain, clinical logistics, specialty drug handling) commanding premium contracts.
- Cross‑selling between wholesale, pharmacy retail, and self-medication channels to increase basket value.
- Recurring revenue from medical IT systems and long-term service agreements improving margin stability.
- High share of revenue from wholesale exposes the company to volume and pricing pressure but benefits from scale advantages.
- Diversification into pharmacies, manufacturing, OTC, and IT reduces single-segment risk and captures margin at multiple points in the value chain.
- Capital allocation focuses on logistics capacity, digital services, and selective manufacturing investments to support margin expansion.
Alfresa Holdings Corporation (2784.T): How It Makes Money
Alfresa Holdings generates profits primarily through a diversified set of healthcare businesses centered on pharmaceutical distribution, logistics, and related upstream and downstream activities. Its core model leverages large-scale purchasing, efficient distribution networks, and value-added services to hospitals, clinics, pharmacies, and manufacturers.- Wholesale pharmaceutical distribution: national drug supply to pharmacies, hospitals, and dispensing chains with economies of scale and long-term contracts.
- Logistics and supply-chain services: cold-chain and regulated logistics for pharmaceuticals and medical supplies.
- Manufacturing and trading of active pharmaceutical ingredients (APIs) and diagnostic reagents-higher-margin growth focus.
- Retail pharmacy operations and pharmacy support services (dispensing, medication management).
- Contract services and regulatory/compliance consulting for domestic and international clients.
| Metric | Value |
|---|---|
| Market capitalization (as of 2025-12-19) | ¥443.58 billion |
| Consolidated revenue (FY ending 2025-03-31) | ¥2.96 trillion (▲3.59% YoY) |
| Debt-to-equity ratio | 0.06 |
| Current ratio | 1.21 |
| Forward P/E | 13.70 |
- International expansion: leveraging distribution know-how and regulatory compliance expertise to enter or deepen presence in Asia and other markets.
- Focus on high-margin segments: scaling APIs and diagnostic reagents to lift overall profitability and margin profile.
- Stable balance sheet: low leverage (debt-to-equity 0.06) supports M&A, capex for logistics, and targeted investment in growth areas.
- Operational resilience: steady current ratio (1.21) and predictable cash flows from distribution contracts underpin financial stability.
Alfresa Holdings Corporation (2784.T) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.